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Abstract
Telmisartan is an angiotensin II receptor blocker with peroxisome proliferator–activated receptor–γ agonistic properties. Telmisartan
prevents weight gain and decreases food intake in models of obesity and in glitazone-treated rodents. This study further investigates the
influence of telmisartan and pioglitazone and their association on weight gain and body composition by examining their influence on
neuroendocrine mediators involved in food intake. Male C57/Black 6 mice were fed a high-fat diet, weight matched, and randomized in 4
treatment groups: vehicle, pioglitazone, telmisartan, and pioglitazone-telmisartan. Weight gain, food and water intake, body composition,
plasma leptin levels, and the hypothalamic expression of neuroendocrine mediators were analyzed. Additional studies were performed with
irbesartan and in angiotensin II 1A receptor–knockout mice. Telmisartan abolished weight and fat gain in vehicle- and pioglitazone-treated
mice while decreasing food intake, the hypothalamic expression of the agouti-related protein, and plasma leptin levels. Modifications in
neuropeptide Y and proopiomelanocortin were not consistent with changes in food intake. The effects on weight gain and expression of the
agouti-related protein were intermediate with irbesartan. The effects of telmisartan on weight gain were even more pronounced in angiotensin
II 1A receptor–knockout mice. This study confirms the anorexigenic effects of telmisartan in mice fed a high-fat diet and suggests for the first
time a functional role of telmisartan on hypothalamic orexigenic agouti-related protein regulation. These anorexigenic properties abolish both
weight gain and body composition modifications in fat-fed and glitazone-treated mice. The anorexigenic properties are independent from the
angiotensin II 1A receptor.
1. Introduction
Telmisartan is an angiotensin II receptor antagonist
currently used as an efficient long-duration antihypertensive
agent [1]. Although its use in clinical practice is principally
to decrease blood pressure, in vitro studies have demon-
strated that telmisartan may have additional effects beyond
its antihypertensive properties [2]. Some structural simila-
rities between telmisartan and pioglitazone led to the
hypothesis and demonstration that telmisartan interacts
with the peroxisome proliferator–activated receptor
(PPAR)–γ receptor [3]. In vitro, telmisartan displays roughly
a third of the PPAR-γ agonist activity of pioglitazone or
rosiglitazone [3-5], an effect independent from the AT-1
receptor. In vivo, telmisartan decreases indexes of insulin
resistance in some models of insulin resistance [3,4], a
finding confirmed by short-term studies in insulin-resistant
hypertensive subjects [6,7]. These properties were not
attributed to a class effect, as they were not observed with
some other angiotensin II receptor antagonists such as
valsartan [8] or losartan [3].
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A very important observation is that, despite its PPAR-γ
properties that induce adipocyte differentiation, telmisartan
is not associated with weight gain [5]. In contrast, the PPAR-
γ agonistic properties of rosiglitazone and pioglitazone are
associated with a substantial gain in weight mainly through
the generation of metabolically active adipocytes. This is a
burden for patients treated with these agents that can
negatively influence their prescription. Recently, we demon-
strated that telmisartan attenuates the weight gain in rodents
fed a high-fat diet and treated with pioglitazone without
interfering with the insulin-sensitizing properties of piogli-
tazone [9]. Although there may be several mechanisms
involved, decreased food intake has been observed in
different settings with telmisartan and could be a very
important contributor to reduction in weight gain [9,10].
The goal of this study was to investigate the influence of
telmisartan and pioglitazone and their association on weight
gain, body composition, and neuroendocrine mediators
involved in food intake in a mouse model of dietary fat–
induced obesity. In addition, the effects of telmisartan were
compared with those of irbesartan, another angiotensin II
receptor antagonist known to have intrinsic PPAR-γ
agonistic properties [4]. To explore whether the effects of
telmisartan were dependent on an intact angiotensin II 1A
receptor (AT-1A), knockout (KO) mice for the AT-1A
receptor were studied.
2. Materials and methods
Male C57/Black 6 mice (Charles River Laboratories Iffa
Credo, Lyon, France), aged 8 weeks, had ad libitum access to
water and to a high-fat diet consisting (by energy) of 45% fat,
34% carbohydrates, and 21% protein (Diet 2126; Provimi
Kliba, Cossonay, Switzerland). All animals were caged
singly in a temperature-controlled room (22°C ± 1°C) with a
12-hour light/dark cycle.
2.1. Experiment 1
After 10 weeks of treatment with the high-fat diet, mice
were matched for weight and randomized to the 4 treatment
groups: vehicle, pioglitazone (20 mg/[kg d]), telmisartan (5
mg/[kg d]), and pioglitazone-telmisartan (n = 6 in each
group) for 6 weeks. Pioglitazone was incorporated in the diet
(0.24 g/kg), and telmisartan was added in drinking water at a
concentration of 0.025 to 0.1 g/L to match an average intake
of 5 mg/(kg d). Food intake, water intake, and body weight
were measured every 1 to 3 days.
2.2. Experiment 2
To examine the specificity of telmisartan on changes in
body composition, additional male C57/Black 6 mice aged 8
weeks were treated with telmisartan (5 mg/[kg d], n = 8),
irbesartan (100 mg/[kg d], n = 8), and vehicle (n = 7)
following the identical protocol as above. Irbesartan was
added in drinking water to match an average intake of 100
mg/(kg d).
2.3. Experiment 3
To examine whether the effects of telmisartan were
dependent of the AT-1 receptor, angiotensin II 1A receptor–
KO mice (B6.129P2-Agtr1tm1Unc/J) were treated with
telmisartan (5 mg/[kg d], n = 8) or vehicle (n = 7) following
the identical protocol as above.
Body composition and hypothalami were examined in all
treated wild-type mice. At the end of the treatment period,
animals were killed by decapitation for the determination of
body composition. Arterial blood was collected for bio-
chemical analysis in the telmisartan- and pioglitazone-
treated mice. Hypothalami were removed and flash-frozen
in liquid nitrogen. The headless carcasses were dried to a
constant weight in an oven maintained at 70°C and
subsequently homogenized. Samples of the homogenized
carcass were analyzed in triplicate for fat content by the
Soxhlet extraction method [11]. Total body water was
calculated from the difference between body weight and
carcass dry weight, whereas fat-free dry mass (a proxy for
body protein mass) was calculated from the difference
between carcass dry weight and carcass fat [12].
To exclude a deleterious effect of telmisartan on the well-
being of mice, a subgroup of male C57/Black 6 mice aged 8
weeks was treated with telmisartan and vehicle at the same
doses as above (n = 5 in each group) and separated
individually in cages with a running wheel able to measure
the total distance performed by each mouse over 25 days.
Results were expressed as total kilometers performed on the
running wheel.
2.3.1. Reverse transcriptase polymerase chain reaction
Hypothalami were homogenized at 4°C, and total RNA
was extract using RNAeasy extraction kit (Qiagen, Hom-
brechtikon, Switzerland). First-strand complementary DNA
was synthesized from 1 μg of RNA and random primer in a
20-μL reaction volume using random primer and SuperScript
II (Invitrogen, Carlsbad, CA) according to the manufacturer's
instructions. Relative expression of neuropeptide Y (NPY),
proopiomelanocortin (POMC), agouti-related protein (AgRP),
and β2-microglobulin (reference gene) was then assessed by
real-time polymerase chain reaction using the LightCycler
technology (Roche Diagnostics, Rotkreuz, Switzerland) with
the Takara SYBR Green (Takara Bio Inc, Shiga, Japan).
Complementary DNAs of interest were amplified using the
following specific primers synthesized by Microsynth
(Windish, Switzerland): sNPY (5′-tccgctctgcgacactacat-3′) and
asNPY (5′-tgttttccttcattaagaggtctga-3′), sPOMC (5′-catctttgtc-
cccagagagc-3′) and asPOMC (5′-atggaggtctgaagcaggag-3′),
sβ2-microglobulin (5′-cacccccactgagactgataca-3′) and asβ2-
microglobulin (5′-cgatcccagtagacgctcttg-3′), and sAgRP (5′-
accttagggaggcacctcat-3′) and asAgRP (5′-agcaacattgcagtcag-
cat-3′). All samples were quantified in at least 2 runs to obtain
an interassay coefficient of variation less than 10%, and a
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negative control reaction in the absence of template was always
added for each primer pair. Relative expression was then
determined using crossing point values and amplification
efficiencies of the target gene and the reference gene.
2.4. Biochemical measurements
Blood glucose levels were determined with the Gluc-
ometer Elite XL (Bayer, Basel, Switzerland). Plasma insulin
was determined by enzyme-linked immunosorbent assay
(ELISA) (Rat/Mouse Insulin ELISA Kit; LINCO Research,
St Charles, MO). Plasma leptin was measured by ELISA
(Mouse Leptin ELISA Kit, LINCO Research). Insulin
resistance index at baseline was assessed by homeostasis
model assessment (HOMA-IR) [13].
2.5. Statistical analysis
Data are expressed as means ± SEM. The statistical
significance of differences between the treatment groups
was evaluated by analysis of variance (ANOVA) (Mini-
tab, State College, PA) followed by Fisher test for
multiple comparisons. A level of P b .05 was considered
statistically significant.
Procedures used in this study were in accordance with
principles of animal care and according to the institutional
guidelines. The protocol was reviewed and approved by an
independent ethical committee for animal research.
3. Results
3.1. Glucose, insulin, and HOMA-IR
Plasma glucose, insulin, and HOMA-IR levels decreased
slightly but not significantly with pioglitazone and telmi-
sartan in different treatment groups (Table 1).
3.2. Weight, total food intake, water intake, and HOMA-IR
Pioglitazone-treated mice increased rapidly their body
weight, which remained significantly higher than vehicle-
treated mice. Telmisartan significantly prevented the
increase in body weight induced by the high-fat diet in
vehicle- or pioglitazone-treated mice. The weights were
equivalent with telmisartan whether vehicle or pioglitazone
treated. Telmisartan significantly decreased to the same
extent the total food intake in vehicle- or pioglitazone-treated
mice. Food intake was strongly correlated to final weight
gain (R2 = 56.5%, P b .001). Telmisartan significantly
increased water intake in vehicle- and pioglitazone-treated
mice (P b .001). Pioglitazone did not have any effect on
water intake (Table 2, Figs. 1-3).
The effects of irbesartan on weight and food intake were
intermediate to those of telmisartan. Weights were signifi-
cantly lower in irbesartan-treated mice than in vehicle-
treated mice but remained slightly higher than in telmisartan-
treated mice.
The effects of telmisartan on weight changes were rapid,
sustained, and significant in angiotensin II 1A KOmice. Food
intake decreased significantly with telmisartan in KO mice.
3.3. Body composition
Final weight correlated strongly with fat and dry weight
(R2 = 90.2%, P b .001 and R2 = 94%, P b .001, respectively)
but not with water content (R2 = 55.8%, P N .05).
Pioglitazone-induced weight gain was due not to an increase
in water but to an increase in fat weight. Telmisartan
decreased very significantly fat weight in vehicle- and
pioglitazone-treated mice while increasing fat-free lean
mass. Differences in the 2 protocols are due to the fact that
the mice were heavier at the beginning of the study in the
second protocol. Irbesartan effects on body composition
were intermediate to those of telmisartan (Table 3).
3.4. Neuroendocrine mediators
Plasma leptin levels were correlated with weight (P b
.05) and were lower in telmisartan-treated groups (ANOVA:
Table 1
Glucose insulin levels in different treatment groups (experiment 1)
Group Glucose (mmol/L) Insulin (U/mL) HOMA-IR
Vehicle 10.7 ± 0.6 1.0 ± 0.2 0.46 ± 0.08
Telmisartan 9.7 ± 0.4 0.72 ± 0.19 0.32 ± 0.08
Pioglitazone 9.2 ± 0.3 0.67 ± 0.11 0.27 ± 0.04
Pioglitazone-telmisartan 10.7 ± 0.4 0.65 ± 0.13 0.29 ± 0.05
ANOVA NS NS NS
NS indicates not significant.
Table 2
Weight, total food intake, total water intake, and HOMA at the end of
experiment
Initial
weight (g)
Final
weight (g)
Food
intake (g)
Water
intake (g)
Experiment 1
Vehicle 28.4 ± 1.0 30.8 ± 0.9 104 ± 6.4 172.8 ± 15.2
Telmisartan 28.5 ± 0.9 27.2 ± 1.1⁎,† 91 ± 3.1⁎,† 247.7 ± 14.6⁎,†
Pioglitazone 28.5 ± 0.7 32.8 ± 0.7⁎ 105.5 ± 1.0 171.9 ± 5.3
Pioglitazone-
telmisartan
28.5 ± 0.6 26.9 ± 1.0⁎,† 90.5 ± 2.7⁎,† 247.3 ± 6.2⁎,†
ANOVA NS b.001 .015 b.001
Experiment 2
Vehicle 31.5 ± 1.2 35 ± 1.6 105.9 ± 5.1 191.5 ± 3.4
Irbesartan 30.9 ± 0.7 30.5 ± 1.6⁎ 100.5 ± 9.2 215.9 ± 12
Telmisartan 31.0 ± 1.2 28.2 ± 0.5⁎ 92.5 ± 5.9⁎ 238.9 ± 15⁎
ANOVA NS .005 .048 .03
Experiment 3
Vehicle KO 36.4 ± 0.8 39.7 ± 1.4 127.3 ± 4.2 199 ± 10
Telmisartan
KO
37.8 ± 0.9 32.8 ± 1.0⁎ 112.8 ± 2.7⁎ 301 ± 23⁎
t Test NS .001 .01 .002
⁎ P b .05 vs vehicle.
† P b .05 vs pioglitazone.
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P b .01). Telmisartan significantly prevented the increase in
plasma leptin level induced by pioglitazone (P b .05). The
NPY levels increased significantly in the pioglitazone-
telmisartan group. The POMC levels were not influenced
by telmisartan or pioglitazone. Telmisartan induced a
significant decrease in AgRP expression in vehicle- and
pioglitazone-treated animals (P b .05). In Fig. 4, results
were pooled together from experiments 1 and 2 and
expressed as percentage variation from control (100%).
Expression of the AgRP with telmisartan remained
significantly lower than controls, and effects of irbesartan
were intermediate (Table 4, Fig. 4).
Fig. 1. Experiment 1: percentage change in body weight from baseline in vehicle-, telmisartan-, pioglitazone-, and pioglitazone-telmisartan–treated mice.
*#P b .05.
Fig. 2. Experiment 2: percentage change in body weight from baseline in vehicle-, irbesartan-, and telmisartan-treated mice. *#P b .05.
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3.5. Total kilometers achieved with running wheel
Vehicle-treated mice ran 295.4 ± 39.2 km and telmisartan-
treated mice ran 330.1 ± 28.4 km over 25 days in their cages
(P not significant).
4. Discussion
This study confirms that telmisartan has favorable effects
on food intake, weight gain, and fat mass in rodents exposed
to a high-fat diet and/or to a glitazone. It extends previous
observations by demonstrating that these effects are
independent from the angiotensin II 1A receptor. Although
many mechanisms may be involved, the significant decrease
in the expression of the orexigenic hypothalamic AgRP
provides mechanistic insights into the anorexigenic proper-
ties of telmisartan.
The hypothalamus participates in a complex network of
signals involved in the elaboration of orexigenic and
anorexigenic signals. A well-recognized orexigenic neuro-
modulator is the AgRP, an endogenous antagonist of the
melanocortin receptor, which interferes with the actions of the
anorectic melanocyte-stimulating peptide encoded by the
POMC gene. The AgRP is coexpressed with NPY within the
hypothalamic arcuate neurons, and its expression is inhibited
by adipocyte-released leptin and increased by food restriction.
The AgRP expression or plasma levels have been associated
with body weight. The expression is increased in mouse
models of obesity [14], and plasma levels have been positively
correlated to body mass index in humans [15]. In contrast,
AgRP-deficient mice have an age-related lean phenotype and
increased metabolic rate [16]. Corticosterone implants
increase hypothalamic AgRP messenger RNA (mRNA)
expression [17]. To our knowledge, no pharmacologic drug
given orally has been shown to decrease AgRP expression in
Fig. 3. Experiment 3: percentage change in body weight from baseline in vehicle- and telmisartan-treated AT-1A receptor KO mice. *P b .05.
Table 3
Body composition of mice at end of study
Dry weight Water Body fat % Fat-free lean mass % Fat
Experiment 1
Vehicle 11.2 ± 0.9 19.7 ± 0.2 5.45 ± 0.8 18.6 ± 0.3† 17.4 ± 2.3
Telmisartan 9.1 ± 0.8 † 18.2 ± 0.5⁎,† 3.77 ± 0.7† 19.6 ± 0.4 13.5 ± 1.9⁎,†
Pioglitazone 13.6 ± 0.7⁎ 19.2 ± 0.2 7.9 ± 0.7⁎ 17.3 ± 0.4† 23.9 ± 1.7
Pioglitazone-
telmisartan
8.6 ± 0.6⁎,† 18.2 ± 0.3⁎,† 3.45 ± 0.5† 19.4 ± 0.4† 12.6 ± 1.5⁎,†
ANOVA .001 .007 .001 .001 .001
Experiment 2
Vehicle 16.2 ± 1.3 18.8 ± 0.4 9.2 ± 1.1 20.0 ± 0.3 25.9 ± 1.7
Irbesartan 12.7 ± 1.3⁎ 17.8 ± 0.3⁎ 6.2 ± 1.1⁎ 21.5 ± 0.6⁎ 19.3 ± 2.7⁎
Telmisartan 10.8 ± 0.4⁎ 17.4 ± 0.2⁎ 4.5 ± 0.4⁎ 22.4 ± 0.3⁎ 15.9 ± 1.0⁎
ANOVA .007 .02 .006 .008 .008
⁎ P b .05 vs vehicle.
† P b .05 vs pioglitazone.
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mice. Our study demonstrates for the first time a significant
influence of the orally administered angiotensin II receptor
blocker telmisartan on the hypothalamic expression of AgRP.
Because experimental studies show that stress can
decrease the expression of the AgRP mRNA expression
in arcuate nucleus neurons [18], we wanted to exclude a
deleterious effect of telmisartan on the well-being of mice.
Mice treated with telmisartan ran a slightly longer distance
using running wheel than vehicle-treated mice, suggesting
that the general condition of these mice was satisfactory.
Interestingly, a study showed that AgRP-deficient mice
have an increase in their spontaneous physical activity [16].
Whether the telmisartan-induced decrease in the expression
of the AgRP influenced independently and directly the
food intake and spontaneous physical activity still needs
further investigations.
In this study, other central neuroendocrine factors were
not involved such as POMC or NPY. Neuropeptide Y and
AgRP are coexpressed in hypothalamic arcuate neurons
and respond similarly to food deprivation and leptin
administration. In our study, telmisartan-induced changes
in AgRP and NPY did not parallel, suggesting a
differential regulation of both peptides in this particular
experimental setting. In agreement with our observations,
recent studies demonstrated that there may be a differential
expression of both peptides, as during stress or short
photoperiod [18,19]. In contrast to AgRP changes, the
NPY response in the pioglitazone-telmisartan group was
similar to that observed as a consequence of food
deprivation, weight loss, and decreased leptin levels.
Therefore, the anorexigenic properties of telmisartan
could result from a decrease in the expression of the
AgRP that is other than or beyond NPY modulation.
One study demonstrated that telmisartan has a favorable
effect on weight gain by decreasing food intake in addition to
increasing energy expenditure and brown adipose tissue
uncoupling protein 1 (UCP-1) expression [20]. Another
study showed that the intracerebroventricular administration
of AgRP results in an increase in food intake and a decrease
in brown adipose tissue UCP-1 expression [21]. The
decrease in the hypothalamic expression of the AgRP
found in our study may be the common pathway resulting
in both favorable effects of telmisartan on brown adipose
tissue UCP-1 expression and food intake.
Rodents express 2 isoforms of the AT-1 receptor (AT-1A
and AT-1B), which are highly homologous and inhibited by
angiotensin II receptor antagonists. The expression of the
AT-1A receptor in the brain exceeds that of the AT-1B
receptor. Importantly, the telmisartan-induced decrease in
food intake was associated with a significant increase in
water intake in wild-type and in AT-1A receptor KO mice,
which excludes an aversion to telmisartan in drinking water
as the cause of the decreased food intake. Interestingly, in
vehicle-treated mice, water intake was not decreased in
AT-1A receptor KO mice compared with wild-type mice.
These results are in contradiction with the findings that the
overexpression of brain AT-1A receptors increases water
intake and that some angiotensin II receptor antagonists
(irbesartan and losartan) decrease water intake [22-24]. We
cannot exclude that the measured increase in water intake
may have been biased by a higher spillage due to a higher
activity of the telmisartan-treated mice and playing with
water bottles. Neither can we exclude that the higher water
intake may have increased energy expenditure, although this
possible interaction has recently been questioned [25].
Although controversial and poorly studied, we cannot
exclude an influence of the larger fluid intake on decreased
food intake in this model. However, if increased drinking
behavior was the main cause of decreased food intake, the
consequent food deprivation would have been associated
with an increase in hypothalamic AgRP expression, which
was not the case.
Table 4
Plasma leptin levels and hypothalamic mRNA levels of peptides implicated in food intake control (experiment 1)
Group Leptin (ng/mL) NPY (% vehicle) POMC (% vehicle) AgRP (% vehicle)
Vehicle 7.1 ± 1.4 100 ± 9.05 100 ± 13.71 100 ± 7.60
Telmisartan 5.2 ± 1.5 92.1 ± 5.53 87.1 ± 6.31 81.3 ± 4.10⁎
Pioglitazone 12.9 ± 2.3 91.8 ± 12.72 109.4 ± 18.39 107.8 ± 4.66
Pioglitazone-telmisartan 4.2 ± 1.1† 184.6 ± 28.9⁎,† 158.8 ± 39.67 88.7 ± 2.53†
ANOVA .005 .002 NS .0067
⁎ P b .05 vs vehicle.
† P b .05 vs pioglitazone.
Fig. 4. Experiments 1 and 2: mRNA expression of AgRP in comparison with
controls (100%). *P b .05.
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The fact that the anorexigenic properties of telmisartan
were still present in AT-1A receptor KO mice suggests that
some actions of telmisartan are not mediated by the AT-1A
receptor in accordance with the AT-1 receptor–independent
PPAR-γ properties of telmisartan [5]. However, this study
cannot exclude a possible central effect of telmisartan on the
AT-1B receptor.
Pioglitazone induced a rapid and sustained increase in
body weight. Although fluid retention has been demon-
strated with pioglitazone after 6 days of treatment [26], long-
term treatment (6 weeks) in our study did not demonstrate
any fluid retention but an increase in fat mass. Pioglitazone
was only associated with a slight but nonsignificant increase
in food intake in this model, in contrast to the marked
pioglitazone-induced hyperphagia we observed previously
in the Zucker rat model of obesity [9]. No modification of
central neuroendocrine factors was demonstrated with
pioglitazone in this study or in the Zucker rat model (data
not shown). Only leptin was increased with pioglitazone and
was overall very strongly correlated to percentage fat
composition (R2 = 89.1%, P b .001). This study shows that
the effects of telmisartan on pioglitazone-induced changes in
body composition in mice are pronounced without changing
the insulin-sensitizing properties of pioglitazone, as we
already demonstrated previously in rat models of obesity [9].
These effects are strongly mediated through the decreased
food intake; however, an influence of telmisartan on
pioglitazone-induced adipogenesis or on energy expenditure
is not excluded.
The mechanisms of body weight regulation are complex,
involving both central and peripheral signals modulating
caloric intake and total energy expenditure. In addition, some
drugs can increase fat mass, particularly the powerful insulin
sensitizers and PPAR-γ agonists pioglitazone and rosiglita-
zone. Telmisartan has unique properties beyond its angio-
tensin II antagonistic effects. This study confirms the
anorexigenic effects of telmisartan in mice treated with a
glitazone and/or fed a high-fat diet and suggests that the
effect is AT-1A receptor independent and is mediated through
a decrease in the neuroendocrine orexigenic modulator
AgRP. In this study, irbesartan had favorable effects on
weight gain and on the expression of the AgRP that were
intermediate to telmisartan. Further studies are needed to
explore in more details the neuroendocrine effects of these
angiotensin II receptor blockers, in particular by examining
which signaling pathways are involved and whether they
depend on their selective PPAR-γ modulating activity. If
these observations are confirmed in clinical trials, the use of
telmisartan may be an interesting option to regulate diet-
induced and glitazone-induced weight gain.
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